MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.biopha.2026.119724

Медицинская библиотека · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026

RGD-functionalized cannabidiol lipid nanoparticles improve brain delivery and alleviate cognitive and metabolic dysfunction via gut-brain axis modulation in an Alzheimer's disease model.

Lapmanee Sarawut, Thonapan Natchayaporn, Sriwong Siriwan, Bhubhanil Sakkarin, Wongchitrat Prapimpun, Charoenphon Natthawut, Ngernsutivorakul Thitaphat, Hooncharoen Khemmaphat, Bunwatcharaphansakun Phichaporn, Khongkow Mattaka, Namdee Katawut

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and neuronal loss. Evidence links gut-brain axis dysfunction and metabolic disturbances to AD. Although cannabidiol (CBD) has neuroprotective effects, its use is limited by poor bioavailability and brain delivery.

METHODS

Arginylglycylaspartic acid (RGD)-functionalized, CBD-loaded lipid nanoparticles (CBD/LNP-RGD) were developed to enhance targeted delivery across the blood-brain barrier (BBB) via integrin αvβ3-mediated transcytosis. Cellular uptake and BBB permeability were evaluated in vitro. Anti-inflammatory and antioxidant effects were assessed in Aβ/LPS-induced models. In vivo efficacy was examined using cognitive-behavioral tests, including the novel object recognition and the Morris water maze. Metabolic parameters, histopathology, synaptic protein expression, and gut barrier integrity were also evaluated.

RESULTS

CBD/LNP-RGD demonstrated a 3-fold increase in cellular uptake and a 65% enhancement in BBB transport compared to non-targeted formulations. Treatment significantly reduced pro-inflammatory cytokines (i.e., IL-6 and TNF-α, p < 0.001) and intracellular reactive oxygen species (p < 0.001). In vivo, CBD/LNP-RGD improved cognitive performance comparable to Donepezil (p < 0.001). Additionally, it normalized glycemic control, insulin resistance, and triglyceride levels without hepatic or renal toxicity. At the tissue level, CBD/LNP-RGD reduced Aβ and tau pathology, restored short-chain fatty acids, preserved hippocampal neuronal integrity, and upregulated synaptophysin and PSD-95 proteins. Enhanced intestinal barrier function was evidenced by increased expression of tight junction proteins ZO-1 and occludin.

CONCLUSIONS

CBD/LNP-RGD represents a multifunctional nanotherapeutic platform that improves brain delivery and exerts neuroprotective, anti-inflammatory, antioxidant, and metabolic regulatory effects. Its ability to modulate both central pathology and the gut-brain axis highlights its potential as a disease-modifying strategy for Alzheimer's disease.

Для цитирования: Lapmanee Sarawut, Thonapan Natchayaporn, Sriwong Siriwan, Bhubhanil Sakkarin, Wongchitrat Prapimpun, Charoenphon Natthawut, Ngernsutivorakul Thitaphat, Hooncharoen Khemmaphat, Bunwatcharaphansakun Phichaporn, Khongkow Mattaka, Namdee Katawut. RGD-functionalized cannabidiol lipid nanoparticles improve brain delivery and alleviate cognitive and metabolic dysfunction via gut-brain axis modulation in an Alzheimer's disease model.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2026. DOI: 10.1016/j.biopha.2026.119724.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.